軟部肉腫市場調査レポート情報：診断別（生検、超音波スキャン、磁気共鳴画像法（MRI）、その他）、治療別（標的療法、化学療法、血管新生阻害薬、放射線療法、手術）、エンドユース別（病院・クリニック、がん研究センター、その他）、地域別（北米、欧州、アジア太平洋地域、その他の地域）産業予測：2032年まで
Soft Tissue Sarcoma Market Research Report Information By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others), By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery) By End Use (Hospitals and Clinics, Cancer Research Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest of the World) Industry Forecast Till 2032
軟部肉腫市場調査レポート情報：診断別（生検、超音波スキャン、磁気共鳴画像法（MRI）、その他）、治療別（標的療法、化学療法、血管新生阻害薬、放射線療法、手術）、エンドユース別（病院・クリニック、がん研... もっと見る
サマリー 軟部肉腫市場調査レポート情報：診断別（生検、超音波スキャン、磁気共鳴画像法（MRI）、その他）、治療別（標的療法、化学療法、血管新生阻害薬、放射線療法、手術）、エンドユース別（病院・クリニック、がん研究センター、その他）、地域別（北米、欧州、アジア太平洋地域、その他の地域）産業予測：2032年まで
市場概要
軟部肉腫の市場規模は、2023年に32億4,852万米ドルと推定され、2032年には62億4,402万米ドルに拡大すると予測され、予測期間中（2024-2032年）の年平均成長率（CAGR）は7.67%である。市場成長の主な要因としては、新製品の導入、革新的な治療法の利用拡大、対象人口の拡大などが挙げられる。
新製品の導入、革新的な医薬品の普及、対象人口の拡大などは、市場成長を牽引する主要な市場ドライバーのひとつである。新規治療薬の発見と開発は、軟部肉腫市場を牽引する重要な要因である。軟部肉腫治療のための革新的な薬剤や治療法の利用可能性は、過去10年間で爆発的に増加した。これらの画期的な医薬品が可能にする治療の選択肢の拡大と有効性の向上は、患者と医師の双方にとって有益である。
市場セグメント別インサイト
血管肉腫、類上皮肉腫、消化管間質腫瘍（GIST）、その他が世界の軟部肉腫市場を構成しており、その種類によって区分されている。消化管間質腫瘍（GIST）セグメントは予測期間中に最も急速に成長するセグメントであり、血管肉腫セグメントは2023年に最大の市場を占めた。
世界の軟部肉腫市場は診断と治療に区分される。診断分野は2023年に最大の市場を占め、治療分野は予測期間中に最も急成長する分野である。診断はさらに以下のカテゴリーに分けられる：超音波スキャン、磁気共鳴画像法（MRI）、生検、その他（PETスキャン、X線など）。標的療法、化学療法、放射線療法、血管新生阻害薬、手術が治療レジメンを構成する。
世界の軟部肉腫市場は、エンドユーザー別に病院・診療所、がん研究センター、その他に区分されている。病院・診療所セグメントは予測期間中に最も急成長しているセグメントであり、2023年には最大の市場を占めている。
地域別展望
本調査では、地域別に北米、欧州、アジア太平洋地域、その他の地域の市場洞察を提供している。2022年、軟部肉腫市場は主に北米が占め、欧州、アジア太平洋地域の順で続く。これは、北米と欧州で軟部肉腫の有病率が高いことに加え、これらの地域に近代的な医療インフラと研究開発活動が存在するためである。
欧州の軟部肉腫市場は、世界市場で2番目に大きな株主である。2021年12月、欧州医薬品庁（EMA）はタズベリック（タゼメトスタット）について、成人の上皮肉腫の治療薬として条件付き販売承認を付与した。
さらに、アジア太平洋地域の軟部肉腫市場は、予測期間中に最も急速な複合年間成長率（CAGR）を記録すると予測されている。2021年9月、中国国家医薬品監督管理局（NMPA）は、軟部肉腫の一種である切除不能または転移性の消化管間質腫瘍（GIST）の治療薬としてAyvakit（avapritinib）を承認した。
主要企業
グラクソ・スミスクライン社（英国）、イーライリリー・アンド・カンパニー社（米国）、ファイザー社（米国）、ブリストル・マイヤーズ スクイブ社（米国）、F.ホフマン・ラ・ロシュ社（ジェネンテック）（スイス）、ジョンソン・エンド・ジョンソン・サービス社（米国）などが軟部肉腫市場の主要プレイヤーである。
ページTOPに戻る
目次 目次
2.
2.
2.
2.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
3.
4.
4.
4.
4.
4.
4.
4.
4.
4.
4.
4.
4.
5.
5.
5.
5.
5.
5.
5.
5.
5.
5.
5.
5.
6.
6.
6.
6.
6.
7.
7.
7.
7.
7.
7.
7.
7.
7.
7.
7.
7.
8.
8.
8.
8.
9.
9.
9.
9.
9.
9.
9.3.2 フランス ..................................................................................................................................................................................................
9.
9.
9.
9.
9.
9.
9.
9.
9.4.3 日本 ...........................................................................................................................................................................................................................
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
10.
10.
10.
10.
10.
10.
10.
10.
10.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.4 F. ホフマン・ラ・ロッシュLtd.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.6 ジョンソン・エンド・ジョンソン株式会社
11.
11.
11.
11.
11.
11.
11.
11.173
11.174
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
11.
ページTOPに戻る
Summary Soft Tissue Sarcoma Market Research Report Information By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others), By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery) By End Use (Hospitals and Clinics, Cancer Research Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest of the World) Industry Forecast Till 2032
Market Overview
The Soft Tissue Sarcoma Market Size was estimated to be USD 3,248.52 Million in 2023 and is expected to increase to USD 6,204.02 Million by 2032, with a compound annual growth rate (CAGR) of 7.67% during the forecast period (2024-2032). The primary market drivers that contribute to market growth include the introduction of new products, the increased utilization of innovative therapies, and a broader target population.
The introduction of new products, the prevalent use of innovative medicines, and an expansion of the target audience are among the key market drivers that are driving market growth. The discovery and development of novel therapeutics are significant factors that are driving the soft tissue sarcoma market. The availability of innovative medications and therapies for the treatment of soft tissue sarcoma has exploded in the past decade. The expanded treatment options and enhanced effectiveness that these groundbreaking pharmaceuticals enable are advantageous to both patients and physicians.
Market segment insights
Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST), and Others comprise the global soft tissue sarcoma market, which is segmented according to its type. The Gastrointestinal Stromal Tumor (GIST) segment is the fastest growing segment during the forecast period, while the Angiosarcoma segment held the largest market in 2023.
The Global Soft Tissue Sarcoma Market has been segmented into Diagnosis and Treatment. The Diagnostic segment was the largest market in 2023, and the Treatment segment is the fastest-growing segment during the forecast period. The diagnosis is further divided into the following categories: Ultrasound Scan, Magnetic Resonance Imaging (MRI), Biopsy, and others, such as PET scan and X-ray. Targeted therapy, chemotherapy, radiation therapy, antiangiogenic drugs, and surgery comprise the treatment regimen.
The Global Soft Tissue Sarcoma Market has been segmented into Hospitals and Clinics, Cancer Research Centers, and others based on End User. The Hospitals and Clinics segment is the fastest-growing segment during the forecast period and held the largest market in 2023.
Regional Perspectives
The study offers market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2022, the soft tissue sarcoma market was primarily dominated by North America, with Europe and the Asia-Pacific region following in that order. This is due to the high prevalence of soft tissue sarcoma in North America and Europe, as well as the presence of modern healthcare infrastructure and R&D activity in these regions.
The European Soft Tissue Sarcoma market is the second greatest shareholder in the global market. In December 2021, the European Medicines Agency (EMA) granted conditional marketing authorization for Tazverik (tazemetostat) for the treatment of epithelioid sarcoma in adults.
Additionally, the Asia Pacific Soft Tissue Sarcoma market is anticipated to experience the most rapid compound annual growth rate (CAGR) during the forecast period. In September 2021, the China National Medical Products Administration (NMPA) approved Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST), a type of soft tissue sarcoma.
Major Players
GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services Inc. (U.S.), and others are among the major players in the Soft Tissue Sarcoma market.
ページTOPに戻る
Table of Contents TABLE OF CONTENTS
1 EXECUTIVE SUMMARY .............................................................................................................. 20
2 MARKET INTRODUCTION ............................................................................................................ 22
2.1 DEFINITION .................................................................................................................................................................. 22
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 22
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 22
2.4 MARKET STRUCTURE .............................................................................................................................................. 22
3 RESEARCH METHODOLOGY ...................................................................................................... 23
3.1 OVERVIEW .................................................................................................................................................................... 23
3.2 DATA FLOW .................................................................................................................................................................. 25
3.2.1 DATA MINING PROCESS ................................................................................................................................. 25
3.3 PURCHASED DATABASE: ......................................................................................................................................... 26
3.4 SECONDARY SOURCES: ............................................................................................................................................ 27
3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 28
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 29
3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 30
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 31
3.6.1 REVENUE ANALYSIS APPROACH ..................................................................................................................... 31
3.7 DATA FORECASTING................................................................................................................................................. 32
3.7.1 DATA FORECASTING TYPE .............................................................................................................................. 32
3.8 DATA MODELING ........................................................................................................................................................ 33
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................................ 33
3.8.2 DATA MODELING: ........................................................................................................................................... 34
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 36
4 MARKET DYNAMICS .................................................................................................................... 38
4.1 INTRODUCTION ........................................................................................................................................................... 38
4.2 DRIVERS ......................................................................................................................................................................... 39
4.2.1 INCREASING INCIDENCE OF SOFT TISSUE SARCOMAS ..................................................................................... 39
4.2.2 RISING AWARENESS ASSOCIATED WITH SOFT TISSUE SARCOMA .................................................................... 39
4.2.3 GROWING APPROVAL OF INNOVATIVE TREATMENT FOR SOFT TISSUE SARCOMA ............................................ 40
4.3 RESTRAINTS ................................................................................................................................................................ 42
4.3.1 SIDE-EFFECTS OF SOFT TISSUE SARCOMA DRUGS ........................................................................................... 42
4.3.2 VOLUNTARY PRODUCT RECALLS BY MARKET PLAYERS ................................................................................... 42
4.4 OPPORTUNITY ............................................................................................................................................................. 44
4.4.1 GROWING GERIATRIC POPULATION ................................................................................................................ 44
4.4.2 INVESTMENTS IN RESEARCH AND DEVELOPMENT .......................................................................................... 44
4.4.3 ONGOING CLINICAL TRIALS FOR SOFT TISSUE SARCOMA ................................................................................ 45
5 MARKET FACTOR ANALYSIS ...................................................................................................... 46
5.1 PORTER'S FIVE FORCES MODEL ........................................................................................................................... 46
5.1.1 THREAT OF NEW ENTRANTS ........................................................................................................................... 46
5.1.2 BARGAINING POWER OF SUPPLIERS ............................................................................................................... 47
5.1.3 THREAT OF SUBSTITUTES .............................................................................................................................. 47
5.1.4 BARGAINING POWER OF BUYERS .................................................................................................................... 47
5.1.5 INTENSITY OF RIVALRY .................................................................................................................................. 47
5.2 IMPACT OF COVID-19 ON GLOBAL SOFT TISSUE SARCOMA MARKET ................................................... 48
5.3 KEY MARKET TRENDS IN THE CHINA SOFT TISSUE SARCOMA MARKET ......................................... 49
5.4 TECHNOLOGICAL ADVANCEMENTS IN CHINA ............................................................................................... 50
5.5 REGULATORY FRAMEWORK IN CHINA ............................................................................................................. 52
5.6 PIPELINE ANALYSIS IN CHINA ............................................................................................................................. 53
5.7 AVERAGE PRICING OF PRODUCTS IN CHINA, 2023 ........................................................................................ 56
6 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE ............................................................. 58
6.1 OVERVIEW .................................................................................................................................................................... 58
6.2 ANGIOSARCOMA ........................................................................................................................................................ 60
6.3 EPITHELIOID SARCOMA .......................................................................................................................................... 61
6.4 GASTROINTESTINAL STROMAL TUMOR (GIST) ............................................................................................. 61
6.5 OTHERS .......................................................................................................................................................................... 62
7 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT ................... 63
7.1 OVERVIEW .................................................................................................................................................................... 63
7.2 DIAGNOSIS .................................................................................................................................................................... 65
7.2.1 BIOPSY .......................................................................................................................................................... 66
7.2.2 ULTRASOUND SCAN ....................................................................................................................................... 66
7.2.3 MAGNETIC RESONANCE IMAGING (MRI) ......................................................................................................... 67
7.2.4 OTHERS ......................................................................................................................................................... 67
7.3 TREATMENT................................................................................................................................................................ 68
7.3.1 TARGETED THERAPY ...................................................................................................................................... 69
7.3.2 CHEMOTHERAPY ............................................................................................................................................ 69
7.3.3 ANTI-ANGIOGENESIS DRUGS ..................................................................................................................... 70
7.3.4 RADIATION THERAPY ..................................................................................................................................... 70
7.3.5 SURGERY ....................................................................................................................................................... 71
8 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER .................................................... 72
8.1 OVERVIEW .................................................................................................................................................................... 72
8.2 HOSPITALS AND CLINICS ........................................................................................................................................ 74
8.3 CANCER RESEARCH CENTERS .............................................................................................................................. 75
8.4 OTHERS .......................................................................................................................................................................... 75
9 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION ........................................................ 76
9.1 OVERVIEW .................................................................................................................................................................... 76
9.2 NORTH AMERICA ....................................................................................................................................................... 77
9.2.1 US.................................................................................................................................................................. 81
9.2.2 CANADA ........................................................................................................................................................ 83
9.3 EUROPE .......................................................................................................................................................................... 85
9.3.1 GERMANY ...................................................................................................................................................... 89
9.3.2 FRANCE ......................................................................................................................................................... 91
9.3.3 UK ................................................................................................................................................................. 93
9.3.4 ITALY ............................................................................................................................................................. 95
9.3.5 SPAIN ............................................................................................................................................................ 97
9.3.6 RUSSIA .......................................................................................................................................................... 99
9.3.7 REST OF EUROPE ............................................................................................................................................ 101
9.4 ASIA-PACIFIC ............................................................................................................................................................... 103
9.4.1 CHINA ............................................................................................................................................................ 107
9.4.2 INDIA ............................................................................................................................................................. 109
9.4.3 JAPAN ........................................................................................................................................................... 111
9.4.4 SOUTH KOREA ................................................................................................................................................ 113
9.4.5 MALAYSIA ..................................................................................................................................................... 115
9.4.6 THAILAND ...................................................................................................................................................... 117
9.4.7 INDONESIA ..................................................................................................................................................... 119
9.4.8 REST OF ASIA-PACIFIC ................................................................................................................................... 121
9.5 SOUTH AMERICA ....................................................................................................................................................... 123
9.5.1 BRAZIL ........................................................................................................................................................... 127
9.5.2 MEXICO ......................................................................................................................................................... 129
9.5.3 ARGENTINA ................................................................................................................................................... 131
9.5.4 REST OF SOUTH AMERICA .............................................................................................................................. 133
9.6 MIDDLE EAST AND AFRICA .................................................................................................................................... 135
9.6.1 GCC COUNTRIES............................................................................................................................................. 139
9.6.2 SOUTH AFRICA ............................................................................................................................................... 142
9.6.3 REST OF MIDDLE EAST AND AFRICA ................................................................................................................ 144
10 COMPETITIVE LANDSCAPE ........................................................................................................ 148
10.1 INTRODUCTION ........................................................................................................................................................... 148
10.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 148
10.3 COMPETITOR DASHBOARD..................................................................................................................................... 149
10.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................................. 150
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL .............................................................................. 150
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 151
10.6.1 PRODUCT APPROVAL ..................................................................................................................................... 151
10.6.2 COLLABORATION ........................................................................................................................................... 151
10.6.3 PRODUCT LAUNCH ......................................................................................................................................... 151
11 COMPANY PROFILES .................................................................................................................. 152
11.1 GE HEALTHCARE ....................................................................................................................................................... 152
11.1.1 COMPANY OVERVIEW ..................................................................................................................................... 152
11.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 153
11.1.3 PRODUCTS/SERVICES OFFERED ...................................................................................................................... 154
11.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 154
11.1.5 SWOT ANALYSIS ............................................................................................................................................ 155
11.1.6 KEY STRATEGIES ............................................................................................................................................ 155
11.2 CANON MEDICAL SYSTEMS CORPORATION .................................................................................................... 156
11.2.1 COMPANY OVERVIEW ..................................................................................................................................... 156
11.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 157
11.2.3 PRODUCT OFFERED ........................................................................................................................................ 157
11.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 158
11.2.5 KEY STRATEGIES ............................................................................................................................................ 158
11.3 NOVARTIS AG .............................................................................................................................................................. 159
11.3.1 COMPANY OVERVIEW ..................................................................................................................................... 159
11.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 160
11.3.3 PRODUCTS OFFERED ...................................................................................................................................... 160
11.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 161
11.3.5 SWOT ANALYSIS ............................................................................................................................................ 161
11.3.6 KEY STRATEGIES ............................................................................................................................................ 161
11.4 F. HOFFMANN-LA ROCHE LTD. ............................................................................................................................. 163
11.4.1 COMPANY OVERVIEW ..................................................................................................................................... 163
11.4.2 FINANCIAL OVERVIEW .................................................................................................................................... 164
11.4.3 PRODUCTS OFFERED ...................................................................................................................................... 164
11.4.4 KEY DEVELOPMENTS ...................................................................................................................................... 164
11.4.5 SWOT ANALYSIS ............................................................................................................................................ 165
11.4.6 KEY STRATEGIES ............................................................................................................................................ 166
11.5 BLUEPRINT MEDICINES CORPORATION ............................................................................................................ 167
11.5.1 COMPANY OVERVIEW ..................................................................................................................................... 167
11.5.2 FINANCIAL OVERVIEW .................................................................................................................................... 168
11.5.3 PRODUCTS OFFERED ...................................................................................................................................... 168
11.5.4 KEY DEVELOPMENTS ...................................................................................................................................... 169
11.5.5 KEY STRATEGIES ............................................................................................................................................ 169
11.6 JOHNSON & JOHNSON INC. ..................................................................................................................................... 170
11.6.1 COMPANY OVERVIEW ..................................................................................................................................... 170
11.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 171
11.6.3 PRODUCTS OFFERED ...................................................................................................................................... 171
11.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 172
11.6.5 SWOT ANALYSIS ............................................................................................................................................ 172
11.6.6 KEY STRATEGIES ............................................................................................................................................ 172
11.7 BRISTOL-MYERS SQUIBB COMPANY .................................................................................................................. 173
11.7.1 COMPANY OVERVIEW .................................................................................................................................... 173
11.7.2 FINANCIAL OVERVIEW .................................................................................................................................... 174
11.7.3 PRODUCTS OFFERED ...................................................................................................................................... 174
11.7.4 KEY DEVELOPMENTS ...................................................................................................................................... 175
11.7.5 KEY STRATEGIES ............................................................................................................................................ 175
11.8 EISAI CO., LTD .............................................................................................................................................................. 176
11.8.1 COMPANY OVERVIEW ..................................................................................................................................... 176
11.8.2 FINANCIAL OVERVIEW .................................................................................................................................... 177
11.8.3 PRODUCTS OFFERED ...................................................................................................................................... 177
11.8.4 KEY DEVELOPMENTS ...................................................................................................................................... 177
11.8.5 SWOT ANALYSIS ............................................................................................................................................ 178
11.8.6 KEY STRATEGIES ............................................................................................................................................ 178
11.9 SIEMENS HEALTHINEERS ...................................................................................................................................... 179
11.9.1 COMPANY OVERVIEW ..................................................................................................................................... 179
11.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 180
11.9.3 PRODUCTS OFFERED ...................................................................................................................................... 180
11.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 181
11.9.5 SWOT ANALYSIS ............................................................................................................................................ 181
11.9.6 KEY STRATEGIES ............................................................................................................................................ 182
11.10 ELI LILLY AND COMPANY ....................................................................................................................................... 183
11.10.1 COMPANY OVERVIEW ..................................................................................................................................... 183
11.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 184
11.10.3 PRODUCTS OFFERED ...................................................................................................................................... 184
11.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 185
11.10.5 KEY STRATEGIES ............................................................................................................................................ 185
12 DATA CITATIONS ......................................................................................................................... 186
ページTOPに戻る
Market Research Future社の 医療分野 での最新刊レポート
-
抗肥満薬市場調査レポート：治療タイプ別（セロトニン・ノルエピネフリン再取り込み阻害薬、選択的セロトニン2C受容体作動薬、ノルエピネフリン・ドパミン再取り込み阻害薬）、リパーゼ阻害薬、GLP-1受容体作動薬、併用薬、その他）、薬物タイプ別（処方薬、市販薬）、作用機序別（中枢性抗肥満薬、末梢性抗肥満薬）、投与経路別（経口、皮下）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、欧州、アジア太平洋、南米、中東、アフリカ） 2035年までの予測
-
ジェネリック医薬品市場調査レポート：適応症別（中枢神経系（CNS）、循環器、泌尿器、腫瘍、呼吸器、その他）、投与経路別（経口、局所、非経口、その他）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）、地域別（北米、欧州、アジア太平洋地域、その他の地域） 2035年までの予測
-
多発性硬化症治療装置市場調査レポート：タイプ別[原発性進行性多発性硬化症（PPMS）、二次性進行性多発性硬化症（SPMS）、再発寛解型多発性硬化症（RRMS）、臨床的孤立症候群（CIS）]、治療装置別[電気刺激装置（機能的電気刺激（FES）、経皮的電気神経刺激（TENS）, 神経刺激装置（脊髄刺激（SCS）, 脳深部刺激（DBS））]、エンドユーザー別（病院＆クリニック, 外来手術センター）、地域別（北米, 欧州, アジア太平洋, 南米, 中東およびアフリカ）2032年までの予測
-
Peptide Cosmetic API Research Report by Application (Anti-Aging & Wrinkle Reduction, Skin Repair & Regeneration, Moisturizing & Hydration, Whitening & Brightening, Hair Care, Anti-Inflammatory & Soothing), by Source (Plant-Derived Peptides, Animal-Derived Peptides, Bioengineered Peptides, Chemically Synthesized), by End-Use Industry (Skincare, Haircare, Injectable Cosmetics, Others), by Region (North America, Europe, APAC, South America, MEA) Forecast till 2035
-
Ischemic Stroke Surgery Market Research Report by Type of Surgery (Thrombectomy, Revascularization Surgery, Carotid Endarterectomy, Angioplasty, Others), by Product Type (Catheters, Aspiration System, Guidewire, Microcatheter, Others), by End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2035
-
アフリカの動物用医薬品市場レポート 動物種別（動物、コンパニオンアニマル）、製品別（医薬品、ワクチン、飼料添加物、衛生用品、診断薬）、流通チャネル別（小売薬局、Eコマース、その他）、地域別（エジプト、ナイジェリア、アルジェリア、チュニジア、リビア、ウガンダ、タンザニア、南スーダン、ケニア、エチオピア、アフリカのその他）の調査レポート情報 2032年までの予測
-
アルテスネート注射剤の世界市場調査レポート：純度別（アルテスネート0.99、アルテスネート0.98）、用途別（マラリア、重症マラリア、脳マラリア、合併症のないマラリア、その他の用途）、エンドユーザー別（病院、診療所、薬局、政府機関、非政府組織）、流通チャネル別（直販、流通業者および卸売業者、小売薬局、オンライン販売）、地域別（北米、欧州、APAC、南米、MEA）2032年までの予測
-
欧州液体クロマトグラフィー機器サービス市場2030年までの予測調査レポート
-
アーユルヴェーダ市場
-
アジア太平洋地域の血液病理学用バイオマーカー市場調査レポート情報：タイプ別（製品・サービス）、癌タイプ別（リンパ腫、白血病）、技術カテゴリー別（NGS、PCR、IHC、FISH、その他）、2032年までの地域別予測
本レポートと同じKEY WORD（soft）の最新刊レポート
よくあるご質問
Market Research Future社はどのような調査会社ですか?
マーケットリサーチフューチャー（Market Research Future）は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。
下記分野については、分野毎に専... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
